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A novel tool to analyze MRI recurrence patterns in glioblastoma
Abstract
At least 10% of glioblastoma relapses occur at distant and even contralateral locations. This
disseminated growth limits surgical intervention and contributes to neurological morbidity. Preclinical
data pointed towards a role for temozolomide in reducing radiotherapy-induced gliomas cell
invasiveness. Our objective was to develop and validate a new analysis tool of magnetic resonance
imaging (MRI) data to examine the clinical recurrence pattern of glioblastomas. MRIcro software was
used to map location and extent of initial preoperative and recurrent tumours on MRI of 63 patients of
the EORTC 26981/22981/NCIC CE.3 study into the same stereotaxic space. This allowed us to examine
changes of site and distance between the initial and the recurrent tumour on the group level. Thirty of
the 63 patients were treated using radiotherapy while the other patients completed a
radiotherapy-plus-temozolomide treatment. Baseline characteristics (median age, Karnofsky
performance score) and outcome data (progression-free survival, overall survival) of the patients
included in this analysis resemble those of the general study cohort. The patient groups did not differ in
the promotor methylation status of methyl-guanyl-methly-transferase (MGMT). Overall frequency of
distant recurrences was 20%. Analysis of recurrence pattern revealed no difference in the size of the
recurrent tumour nor a differential effect on the distance of the recurrences from the preoperative
tumour location between the groups. The data show the feasibility of group-wise recurrence pattern
analysis. An effect of temozolomide treatment on the recurrence pattern in the EORTC
26981/22981/NCIC CE.3 study could not be demonstrated.
A novel tool to analyse MRI recurrence patterns in glioblastoma  
Wolfgang Wick1,9, Roger Stupp2, Anna-Carina Beule1, Jacoline Bromberg3, Antje Wick1, Ulrike 
Ernemann4, Michael Platten1,9, Christine Marosi5, Warren P. Mason6, Martin van den Bent3, Michael 
Weller1, Chris Rorden7, and Hans-Otto Karnath8 on behalf of the European Organisation for Research 
and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. 
 
1Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, 
Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany, Tel. +49-7071-298-2049, Fax +49-7071-29-
5260 
2University of Lausanne Hospitals, Multidisciplinary Oncology Center, 46 Rue du Bugnon, Lausanne 
1011, Switzerland, Tel. +41-213-140156, Fax +41-213-140737 
3Neuro-Oncology Unit, Daniel den Hoed Oncology Center, PO Box 5201, 3008AE Rotterdam, The 
Netherlands, Tel. +31-10-4391-415, Fax +31-10-4391-031 
4Department of Neuroradiology, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, 
Germany, Tel. +49-7071-298-5638, Fax +49-7071-29-5636 
5Department of Internal Medicine I, Clinical Division of Oncology, Medical University Vienna, 6i, 
Wahringer Gürtel 18-20, A-1097 Vienna, Austria. Tel. +43-40400-4429, Fax +43-40400-4451 
6Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON M5G 2M9, Canada, 
Tel. +1-416-946-2277, Fax +1-416-946-2284 
7Department of Communication Sciences & Disorders, University of South Carolina, Columbia, SC 
29208, United States, Tel. +1-803-777-9241, Fax, +1-803-777-3081 
8Section Neuropsychology, Department of Cognitive Neurology, Hertie Institute for Clinical Brain 
Research, University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany, Tel. +49-7071-
298-0465, Fax +49-7071-29-5957
9Department of Neurooncology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 
Heidelberg, Germany, Tel.: +49-6221-56-7075, Fax: +49-6221-56-7554 
 
Running head: Recurrence pattern analysis 
 
Address correspondence to  
Wolfgang Wick, MD 
Department of Neurooncology 
University of Heidelberg 
Im Neuenheimer Feld 400 
D-69120 Heidelberg 
Germany 
Telephone: +49 6221 56-7075 
Facsimile: +49 6221 56-7554 
E-mail: wolfgang.wick@med.uni-heidelberg.de 
  2
ABSTRACT 
 
At least 10% of glioblastoma relapses occur at distant and even contralateral 
locations. This disseminated growth limits surgical intervention and contributes to 
neurological morbidity. Preclinical data pointed towards a role for temozolomide in 
reducing radiotherapy-induced gliomas cell invasiveness. Our objective was to 
develop and validate a new analysis tool of magnetic resonance imaging (MRI) data 
to examine the clinical recurrence pattern of glioblastomas. MRIcro software was 
used to map location and extent of initial preoperative and recurrent tumours on MRI 
of 63 patients of the EORTC 26981/22981/NCIC CE.3 study into the same 
stereotaxic space. This allowed us to examine changes of site and distance between 
the initial and the recurrent tumour on the group level. Thirty of the 63 patients were 
treated using radiotherapy while the other patients completed a radiotherapy-plus-
temozolomide treatment. Baseline characteristics (median age, Karnofsky 
performance score) and outcome data (progression-free survival, overall survival) of 
the patients included in this analysis resemble those of the general study cohort. The 
patient groups did not differ in the promotor methylation status of methyl-guanyl-
methly-transferase (MGMT). Overall frequency of distant recurrences was 20%. 
Analysis of recurrence pattern revealed no difference in the size of the recurrent 
tumour nor a differential effect on the distance of the recurrences from the 
preoperative tumour location between the groups. The data show the feasibility of 
group-wise recurrence pattern analysis. An effect of temozolomide treatment on the 
recurrence pattern in the EORTC 26981/22981/NCIC CE.3 study could not be 
demonstrated. 
Key words: brain tumor, invasiveness, MRIcro, relapse pattern, temozolomide 
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INTRODUCTION 
Patients with malignant glioma face a poor prognosis, with current treatments offering 
limited benefits. However, recent preclinical and clinical studies have improved our 
understanding of gliomas. Longitudinal analyses of glioma patients revealed patterns 
of disease progression that resemble key stages in neurogenesis, implicating that the 
same signaling pathways that play a critical role in regulation of forebrain 
neurogenesis may be involved in the control of tumour aggressiveness.1 Clinically, 
neurooncologists were limited to the assessment of overall survival or immediate 
response to therapy 2 or to comparisons on a single case basis.3  
A major challenge in the management of gliomas is their propensity to infiltrate 
healthy brain tissue. Infiltrating neoplastic cells escape surgery and develop 
resistance to radiation and/or chemotherapy. Further, as a consequence to treatment 
tumour cells may respond with increased migratory and invasive properties. 
Assessing tumour response based solely on anatomic representation of contrast 
enhancement on MRI by WHO criteria or even when taking into account the 
neurological function and performance status of the patient (Macdonald criteria) will 
miss any of these changes in tumour behavior.2  
Novel imaging techniques and algorhythms using perfusion MRI and MR 
spectroscopy allow the identification of areas with enhanced perfusion and 
metabolism within a morphologically homogeneous tumour.4 Diffusion-tensor imaging 
has helped to more precisely identify the association between tumour and anatomic 
fibre tracts and to correlate functions to the anatomical tumour location.5 However, 
these previous studies have focused on individual patients or on a single timepoint. 
Here we conduct a longitudinal study of a group of patients treated within a 
prospective clinical trial, allowing us also to examine whether the pattern of 
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recurrence was different after combined radiochemotherapy versus radiotherapy 
only.  
To this aim we introduce a new tool based on MR imaging to analyze the efficacy of 
brain tumour treatments by measuring the size and location of tumour recurrences 
and allowing us to understand the typical pattern of tumour development after 
different treatment modalities. This method allows uncovering common and 
uncommon anatomical recurrence patterns in relation to the administered treatment. 
This may lead to better understanding of tumour progression, and provides a 
radiological tool for studying and quantifying the effect of novel therapeutic 
interventions, in particular with regards to glioma cell migration and invasiveness.  
To validate this concept, we analyzed the MRI data from a randomized (EORTC 
26981/22981/NCIC CE.3) trial comparing standard radiotherapy with radiotherapy 
with concomitant and adjuvant temozolomide chemotherapy in newly diagnosed 
glioblastoma.6 This cohort was ideal for validating our tool since there is preclinical 
evidence that irradiation enhances glioma cell dissemination and that temozolomide 
has specific anti-invasive properties in addition to its antiproliferative action.7,8 By 
comparing MR data on tumour location obtained prior to any therapy and at 
recurrence or progression of the tumour we asked (i) whether or not there are more 
local recurrences in patients with combined modality treatment because TMZ might 
antagonize the proinvasive properties of therapeutic irradiation, and (ii) whether or 
not there are more distant recurrences in patients with combined modality treatment 
because of the prolonged median time to progression in this arm.  
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MATERIALS AND METHODS 
 
Patients and eligibility 
Patients (N=112) from Lausanne, Rotterdam, Toronto, Tübingen, Utrecht, and 
Vienna were available for screening from the EORTC 26981/22981/NCIC CE.3 trial.6  
 
Analysis of tumour location 
All 63 patients had a glioblastoma affecting unilaterally either the right or the left 
hemisphere. The brain lesions were demonstrated by contrast-enhanced T1-
weighted MRI sequences. The MR scans were oriented along the bicommissural 
plane. Mapping of lesions was performed by two experimenters (A.-C.B. & W.W.) 
blinded to the clinical features of the patients. The boundary of the tumour location at 
baseline and at follow-up was delineated using MRIcro software 9 and mapped on the 
T1-template MRI from the Montreal Neurological Institute 
(www.bic.mni.mcgill.ca/cgi/icbm_view) that is distributed with MRIcro. The template 
scan provides various anatomical landmarks for precisely plotting localization of the 
tumour. Lesions were mapped onto the slices that correspond to MNI z -coordinates -
37, -29, -21, -13, -4, 4, 13, 21, 30, 38, 47, 55, 64, and 72 mm by using the identical or 
the closest matching transversal slices of each individual. Tumours were mapped for 
each individual; with separate tumour maps generated for both the baseline and 
recurrence scan. By transforming each individual brain and lesion into the same 
stereotaxic space, the procedure allowed us to superimpose lesions of different 
individuals to find regions of mutual involvement and conduct subtraction analysis 
(Figure). These techniques are well established in stroke research 9,10 and were 
applied here to tumour lesions for the first time.  
The logic of the analysis is straightforward. First, tumour lesions for a patient group at 
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baseline and lesions for this group at recurrence are defined on the same template 
image (see above). Next, the lesions at baseline are added together, creating an 
overlap image showing the regions of mutual involvement. The same is carried out 
for the lesions at recurrence. Finally, the overlap image of the lesions at recurrence 
are subtracted from the lesion overlap image at baseline. This method creates an 
image that shows regions that are commonly damaged in the patient group at 
recurrence but are typically spared in this group at baseline (coded as positive 
values), regions specifically damaged at baseline (coded as negative values) and 
regions that are damaged/spared in equal proportions between the two stages 
(values near zero). For example, a brain region that is affected by the tumour in all 
patients at recurrence (100%) and three quarters of patients at baseline (75%) would 
have a value of positive 25% (100%-75%) in the subtraction plot. The results can be 
graphically plotted on the same template image; we here used progressively brighter 
shades from red to white to highlight positive values and progressively brighter 
shades of blue to illustrate negative values. Regions with a value of zero (either 
where there were equal numbers of lesions at baseline and recurrence, or where 
none of the observed patients had a lesion) remain uncolored.  
Further, by using MRIcron 10 tumour volume and the location of the center-of-mass of 
the tumour for each individual were computed. The center-of-mass is the mean 
position for all tumour-affected voxels in each of the three spatial dimensions, 
resulting in a single cartesian coordinate (X,Y,Z position). In the case of a single 
spherical tumour, the center-of-mass thus will be located right in its center, while with 
e.g. a U-shaped configuration the center-of-mass may lie outside the tumour itself. 
Likewise this measure is influenced by satellites of the main tumour mass and thus 
sensitive to the development of satellites between baseline and recurrent images. 
Because all lesions were coded in the same sterotaxic space (see above), this 
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procedure allowed us to calculate the anatomical distance between the initial and the 
recurrent tumour on the group level. 
For an additional case-by-case analysis a distant recurrence was defined as a 
recurrence with at least 50% of the tumour mass located outside the borders of the 
contrast enhancing tumour on T1-weighted images plus 2 cm margin. 
 
Ethics 
All participating centers obtained approval for the conduct of the study and further 
studies by their institutional review board according to local and national regulations. 
All patients provided written informed consent. 
 
Statistics 
A two-tailed t-test was conducted to determine if the two treatments influenced the 
size of recurrent tumours and/or the distance of the center-of-mass between the 
baseline and follow-up scan. A sample size of 30 per group would be sufficient to 
detect a 20% difference for the movement of the center-of-mass with a power of 80% 
that would be regarded clinically relevant. 
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RESULTS 
Because of different imaging modalities at diagnosis and recurrence or because MRI 
was missing, 72 patients with localized focal contrast-enhancing disease were 
included in our analyses, all of whom exhibited primarily unilocular contrast-
enhancing tumours. Nine patients had to be excluded as marked mass effect and 
midline shift did not allow the use of the MNI template for the present anatomical 
analysis. Thus, sixty-three patients with glioblastoma treated in the radiotherapy 
group (n=33) or in the radiotherapy-plus-temozolomide group with concomitant and 
adjuvant temozolomide (n=30) were analyzed. Clinical characteristics are 
summarized in the Table. Importantly, patients in both groups did not differ with 
respect to extent of resection or MGMT promoter methylation status. The median 
time between imaging used for the baseline MRI scanning and first histological 
diagnosis was 0.2 months in both groups. The median time between baseline MRI 
and the MRI demonstrating recurrence was 5.4 months in the radiotherapy group and 
7.3 months in the radiotherapy-plus-temozolomide group, comparable to the whole 
study cohort. 
 
Group-wise analysis of recurrence patterns 
Group-wise analysis demonstrate wide spreading of tumour location at baseline and 
at recurrence in the two treatment groups. Tumours affected the temporal, parietal 
and frontal cortices in the left and right hemisphere without obvious preferred 
locations of tumour origin or growth. To investigate whether or not there were 
preferred directions of tumour growth or of tumour reduction after treatment in the 
radiotherapy versus the radiotherapy-plus-temozolomide group, the tumour locations 
at baseline were subtracted from the superimposed tumour locations after treatment 
in each treatment group (for details concerning the subtraction method see 11). For 
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both treatment groups we found no marked anatomical shift of tumour locations after 
treatment. The overlap frequencies after subtraction did not exceed 40% of overlap at 
any location indicating that the anatomical differences between baseline and follow-
up measurement were small and not directionally specific. 
 
No change in the size or recurrence pattern of the recurrent tumours 
Tumour volumes of the recurrent tumours measured in voxels on a per-patient basis 
in both treatment arms were 1.32-fold (+/- 0.36) larger than the original tumours in 
the radiotherapy and 1.29-fold (+/- 0.37) larger in the combined modality arm. Hence, 
the sizes of the recurrent tumours did not differ according to treatment (p = .81). The 
center-of-mass measure allowed us to examine whether treatment influences the 
recurrence at distant sites. For each individual, the distance between baseline and 
follow-up centroids was computed, providing a measure of whether the tumour 
exhibited little movement (e.g. when changes primarily reflect growth or remission of 
the initial tumour) or a large shift in location (e.g. when new satellite tumours have 
developed). A t-test was conducted to determine if the two treatments influence 
movement of the center-of-mass between the baseline and follow-up scan. A two-
tailed t-test revealed no significant difference t(62) = 0.869, p = .387, with a mean 
movement of 11.67 mm (+/- 0.42) for the radiotherapy arm and 12.03 mm (+/- 0.39) 
for the radiochemotherapy arm.  
An additional comparison on a case-by-case basis suggested the same conclusion. 
The frequency of distant recurrences was 23% in the radiotherapy and 18% in the 
radiochemotherapy group (Chi2=1.18, p=0.056). 
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DISCUSSION 
This study was conducted to implement a novel tool for the analysis of brain tumour 
studies by analyzing whether the anatomical recurrence pattern of glioblastoma in 
patients treated with combinational radiochemotherapy with temozolomide and 
adjuvant temozolomide in the EORTC 26981/22981/NCIC CE.3 study 6 is altered 
compared to patients treated with radiotherapy alone. Although the analysis was 
technically feasible, the heterogeneity of imaging modalities (computed tomography 
and MRI) used in the original study, limited the number of eligible patients for this 
analysis since it depends on equal imaging modalities for comparison and required 
MRI scans during the entire follow-up.   
Five-10% recurrent or progressive glioblastomas have been reported to be out of the 
primary tumour field defined by contrast enhancement.12,13 Our data using a pair-
wise comparison for the individual patient with a center-of-mass approach revealed 
an approximate incidence of out-of-field recurrences of 20%. This higher number 
could be due to methodological differences as the determination of distant 
recurrences in older studies did often not rely on MRI. Preclinical studies 8 had 
suggested antiinvasive properties of temozolomide. In addition glioma growth 
patterns, more invasive or more angiogenic may correlate with molecular 
glioblastoma signatures, e.g. activation of the protein kinase-3/Akt or Notch 
pathways.1 However, our clinical data does not support the preclinical hypothesis that 
the improved outcome with combined temozolomide chemoradiotherapy is due to 
reduced tumour cell mobility. The pattern of recurrence, although delayed in TMZ 
treated patients, is comparable, and independent of the analyzed clinical and 
molecular factors (MGMT promoter methylation according to 14). Similarly, one may 
have expected an increased frequency of distant (out of radiation field) recurrences 
due to the presumed radiosensitizing effect and the longer survival. Again, this has 
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not been observed when looking at the site first recurrence or progression. Our 
findings indicate that yet to be identified molecular and cellular determinants 
independent of current treatment is the main driver for tumour progression and 
pattern of recurrence.  
New treatment approaches aiming at molecular targets of both tumour and stroma or 
vasculature (e.g. bevacizumab, cilengitide, enzastaurin or epidermal growth factor 
receptor inhibitors) may also alter the invasiveness of tumour cells, including the risk 
of an increasing cell motility during antiangiogenic treatment. Thus, systematic 
evaluation of recurrence pattern as in our study may be needed to identify changes in 
tumour behavior, and adequate prospective imaging surveillance should be 
implemented in future studies. This could also mean to perform the present analysis 
not only on post-contrast MRI but sequences likely to visualize infiltrative tumor, e.g. 
T2-weighted or fluid attenuated inversion recovery sequences, as well as metabolic 
imaging, e.g. aminoacid positron emission tomography. 
In summary, the current study used tumour boundaries depicted on MRI sequences 
that are transposed onto the MNI template and analysed using MRIcro. It allows 
detection of changes of site and distance between the initial and the recurrent tumour 
on the group level. We did not observe a difference in recurrence pattern between 
the patients treated with radiochemotherapy versus radiotherapy. This recurrence 
pattern analysis may aid the development of combinational therapies that counteract 
the putative pro-invasive adverse effects of therapeutic irradiation or antiangiogenic 
strategies. 
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LEGENDS 
Figure: Overlay tumour location plots of a patient with local versus distant 
recurrence. Illustrated are the initial tumour locations in three transverse sections at 
diagnosis (D), at recurrence after treatment (R) and superimposed (S) for a 
prototypic local recurrence (left panels) as well as a prototypic distant recurrence 
(right panel). Colours encode additional tumour present at recurrence (yellow), 
tumour present at diagnosis but not at recurrence (blue) or tumour present at both 
time points (purple).  
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TABLE 
 
Variable Radiotherapy (n=33) Radiotherapy plus TMZ 
(n=30) 
 value (95% CI) 
Median age [years] 56 56 
Performance Status  [n] 70-80 (13) 
90/100 (20) 
70/80 (12) 
90/100 (18) 
Debulking Surgery [n] 19 18 
MGMT promotor* 
(methylated/unmethylated) 
10/12 10/13 
PFS [months] 5.2 (4.2-5.5) 7.1 (5.8-8.2) 
Survival [months] 12 (11.2-13.2) 14.4 (13.4-16.8) 
CI denotes confidence interval 
*according to 13 
Baseline characteristics of analysed patients. 
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